Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Ludwig JA"" wg kryterium: Autor


Wyświetlanie 1-8 z 8
Tytuł :
Desmoplastic Small Round Cell Tumor Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Results of a Phase 2 Trial.
Autorzy :
Hayes-Jordan AA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. .
Coakley BA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Green HL; Department of Pediatric Surgery, Children's Hospital of Los Angeles, Los Angeles, CA, USA.
Xiao L; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fournier KF; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Herzog CE; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ludwig JA; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
McAleer MF; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Anderson PM; Department of Pediatric Hematology Oncology and Blood and Marrow Transplantation, Cleveland Clinic, Cleveland, OH, USA.
Huh WW; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pokaż więcej
Źródło :
Annals of surgical oncology [Ann Surg Oncol] 2018 Apr; Vol. 25 (4), pp. 872-877. Date of Electronic Publication: 2018 Jan 30.
Typ publikacji :
Clinical Trial, Phase II; Journal Article
MeSH Terms :
Chemotherapy, Cancer, Regional Perfusion*
Cytoreduction Surgical Procedures*
Hyperthermia, Induced*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Desmoplastic Small Round Cell Tumor/*therapy
Peritoneal Neoplasms/*therapy
Adolescent ; Adult ; Chemotherapy, Adjuvant ; Child ; Child, Preschool ; Combined Modality Therapy ; Desmoplastic Small Round Cell Tumor/pathology ; Female ; Follow-Up Studies ; Humans ; Infant ; Male ; Middle Aged ; Peritoneal Neoplasms/pathology ; Prognosis ; Prospective Studies ; Survival Rate ; Young Adult
Czasopismo naukowe
Tytuł :
Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults.
Autorzy :
Wagner MJ; Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Gopalakrishnan V; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ravi V; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Livingston JA; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Conley AP; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Araujo D; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Somaiah N; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Zarzour MA; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ratan R; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Wang WL; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Patel SR; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Lazar A; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ludwig JA; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Benjamin RS; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA .
Pokaż więcej
Źródło :
The oncologist [Oncologist] 2017 Oct; Vol. 22 (10), pp. 1271-1277. Date of Electronic Publication: 2017 Jul 14.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Doxorubicin/*therapeutic use
Ifosfamide/*therapeutic use
Sarcoma, Ewing/*drug therapy
Vincristine/*therapeutic use
Adolescent ; Adult ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Disease-Free Survival ; Doxorubicin/pharmacology ; Female ; Humans ; Ifosfamide/pharmacology ; Male ; Middle Aged ; Vincristine/pharmacology ; Young Adult
Czasopismo naukowe
Tytuł :
Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma.
Autorzy :
Subbiah V; The University of Texas MD Anderson Cancer Center, Houston, Texas. .
Meyer C; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
Zinner R; The University of Texas MD Anderson Cancer Center, Houston, Texas.; Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.
Meric-Bernstam F; The University of Texas MD Anderson Cancer Center, Houston, Texas.
Zahurak ML; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
O'Connor A; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
Roszik J; The University of Texas MD Anderson Cancer Center, Houston, Texas.
Shaw K; The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ludwig JA; The University of Texas MD Anderson Cancer Center, Houston, Texas.
Kurzrock R; The University of Texas MD Anderson Cancer Center, Houston, Texas.; University of California, San Diego, San Diego, California.
Azad NA; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
Pokaż więcej
Źródło :
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2017 Aug 01; Vol. 23 (15), pp. 4027-4034. Date of Electronic Publication: 2017 Apr 04.
Typ publikacji :
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Pyridones/*administration & dosage
Pyrimidines/*administration & dosage
Pyrimidinones/*administration & dosage
Sarcoma/*drug therapy
Sulfonamides/*administration & dosage
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Disease-Free Survival ; Drug-Related Side Effects and Adverse Reactions ; Female ; Humans ; MAP Kinase Kinase Kinase 1/antagonists & inhibitors ; Male ; Middle Aged ; Protein Kinase Inhibitors/administration & dosage ; Pyridones/adverse effects ; Pyrimidines/adverse effects ; Pyrimidinones/adverse effects ; Sarcoma/genetics ; Sarcoma/pathology ; Sulfonamides/adverse effects ; Vascular Endothelial Growth Factor A/antagonists & inhibitors
Czasopismo naukowe
Tytuł :
IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.
Autorzy :
Lamhamedi-Cherradi SE; Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM).
Menegaz BA; Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM).
Ramamoorthy V; Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM).
Vishwamitra D; Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM).
Wang Y; Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM).
Maywald RL; Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM).
Buford AS; Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM).
Fokt I; Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM).
Skora S; Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM).
Wang J; Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM).
Naing A; Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM).
Lazar AJ; Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM).
Rohren EM; Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM).
Daw NC; Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM).
Subbiah V; Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM).
Benjamin RS; Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM).
Ratan R; Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM).
Priebe W; Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM).
Mikos AG; Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM).
Amin HM; Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM).
Ludwig JA; Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM) .
Pokaż więcej
Źródło :
Journal of the National Cancer Institute [J Natl Cancer Inst] 2016 Aug 30; Vol. 108 (12). Date of Electronic Publication: 2016 Aug 30 (Print Publication: 2016).
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Bone Neoplasms/*drug therapy
Bone Neoplasms/*metabolism
Receptors, Somatomedin/*antagonists & inhibitors
Sarcoma, Ewing/*drug therapy
Sarcoma, Ewing/*metabolism
TOR Serine-Threonine Kinases/*antagonists & inhibitors
Adenosine Triphosphatases/antagonists & inhibitors ; Adenosine Triphosphatases/metabolism ; Animals ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Cation Transport Proteins/antagonists & inhibitors ; Cation Transport Proteins/metabolism ; Cell Line, Tumor ; Copper-Transporting ATPases ; Drug Resistance, Neoplasm ; Drug Synergism ; Humans ; Imidazoles/administration & dosage ; Insulin Receptor Substrate Proteins/metabolism ; Male ; Mice ; Mice, SCID ; Neoplasm Transplantation ; Nucleocytoplasmic Transport Proteins/metabolism ; Phosphatidylinositol 3-Kinase/metabolism ; Phosphoinositide-3 Kinase Inhibitors ; Protein Array Analysis ; Pyrazines/administration & dosage ; Pyrimidines/administration & dosage ; Pyrroles/administration & dosage ; Receptor, IGF Type 1 ; STAT3 Transcription Factor/metabolism ; Sirolimus/administration & dosage ; Sirolimus/analogs & derivatives ; Up-Regulation ; p38 Mitogen-Activated Protein Kinases/metabolism
Czasopismo naukowe
Tytuł :
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.
Autorzy :
Schwartz GK; Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. />Tap WD
Qin LX
Livingston MB
Undevia SD
Chmielowski B
Agulnik M
Schuetze SM
Reed DR
Okuno SH
Ludwig JA
Keedy V
Rietschel P
Kraft AS
Adkins D
Van Tine BA
Brockstein B
Yim V
Bitas C
Abdullah A
Antonescu CR
Condy M
Dickson MA
Vasudeva SD
Ho AL
Doyle LA
Chen HX
Maki RG
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2013 Apr; Vol. 14 (4), pp. 371-82. Date of Electronic Publication: 2013 Mar 08.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols*/administration & dosage
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Bone Neoplasms*/drug therapy
Bone Neoplasms*/mortality
Bone Neoplasms*/pathology
Sarcoma*/drug therapy
Sarcoma*/mortality
Sarcoma*/pathology
Antibodies, Monoclonal/*administration & dosage
Sirolimus/*analogs & derivatives
Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized ; Disease-Free Survival ; Drug-Related Side Effects and Adverse Reactions/chemically induced ; Drug-Related Side Effects and Adverse Reactions/pathology ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Grading ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Receptor, IGF Type 1/antagonists & inhibitors ; Receptor, IGF Type 1/immunology ; Receptor, IGF Type 1/metabolism ; Sirolimus/administration & dosage ; Sirolimus/adverse effects ; TOR Serine-Threonine Kinases/antagonists & inhibitors ; TOR Serine-Threonine Kinases/metabolism
Czasopismo naukowe
Tytuł :
Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor.
Autorzy :
Park MS; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230-1402, USA. />Patel SR
Ludwig JA
Trent JC
Conrad CA
Lazar AJ
Wang WL
Boonsirikamchai P
Choi H
Wang X
Benjamin RS
Araujo DM
Pokaż więcej
Źródło :
Cancer [Cancer] 2011 Nov 01; Vol. 117 (21), pp. 4939-47. Date of Electronic Publication: 2011 Apr 08.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Antibodies, Monoclonal, Humanized/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Dacarbazine/*analogs & derivatives
Hemangiopericytoma/*drug therapy
Solitary Fibrous Tumors/*drug therapy
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bevacizumab ; Dacarbazine/administration & dosage ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Recurrence, Local ; Temozolomide ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial.
Autorzy :
Vadhan-Raj S; University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. />Trent J
Patel S
Zhou X
Johnson MM
Araujo D
Ludwig JA
O'Roark S
Gillenwater AM
Bueso-Ramos C
El-Naggar AK
Benjamin RS
Pokaż więcej
Źródło :
Annals of internal medicine [Ann Intern Med] 2010 Sep 21; Vol. 153 (6), pp. 358-67.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Fibroblast Growth Factor 7/*administration & dosage
Sarcoma/*drug therapy
Stomatitis/*prevention & control
Adolescent ; Adult ; Aged ; Antibiotics, Antineoplastic/adverse effects ; Double-Blind Method ; Doxorubicin/adverse effects ; Female ; Fibroblast Growth Factor 7/adverse effects ; Humans ; Male ; Middle Aged ; Mouth Mucosa/drug effects ; Mouth Mucosa/pathology ; Stomatitis/drug therapy ; Young Adult
Czasopismo naukowe
Tytuł :
Review: Ewing sarcoma treatment: a role for bisphosphonates?
Autorzy :
Subbiah V; Department of Pediatrics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Ludwig JA
Pokaż więcej
Źródło :
Clinical advances in hematology & oncology : H&O [Clin Adv Hematol Oncol] 2010 Jul; Vol. 8 (7), pp. 503-4.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Bone Density Conservation Agents/*therapeutic use
Bone Neoplasms/*drug therapy
Diphosphonates/*therapeutic use
Sarcoma, Ewing/*drug therapy
Bone Neoplasms/pathology ; Drug Therapy, Combination ; Humans ; Sarcoma, Ewing/pathology ; Treatment Outcome
Czasopismo naukowe
    Wyświetlanie 1-8 z 8

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies